Recent

% | $
Quotes you view appear here for quick access.

Opko Health, Inc. Message Board

  • cl86cl cl86cl Jun 30, 2013 7:15 PM Flag

    From a new S A article

     

    Conclusion

    If we took the current valuation multiples being assigned to newly successful biotech companies such as Regeneron (REGN), Gilead (GILD), Celgene (CELG), and Biogen (BIIB), we would come up with an average P/E multiple of 31.92. Not surprisingly this is right in the 30 price-to-sales ratio number where OPK is currently valued. Seeing that the current near-term market size OPK is entering is an estimated $43.5B (solely in the territories estimated) and the company will have around 405M shares outstanding following the completion of its acquisition of Prolor Biotech, I see a high chance of the company breaking the $50 a share mark in a few years time and possibly much higher if all of the discussed products are on the market in the outer 2016-18 years. Since OPK is what investors refer to as a speculative stock, there is always a high degree of risk involved in making an investment. I have based my rationale for investing in OPK on the following:

    A large and high-demand product pipeline.
    A top-notch management team that has already built and sold two highly successful pharmaceutical companies to Teva (TEVA) and Schering Plough.
    Massive insider buying on a scale I have never personally seen before.
    A gut instinct that this company has all the stars aligned to make it a huge success.

    This topic is deleted.
 
OPK
17.78+0.20(+1.14%)May 22 4:01 PMEDT